186431-96-9Relevant academic research and scientific papers
METHODS OF TREATING LIVER FIBROSIS USING CALPAIN INHIBITORS
-
Paragraph 0391, (2020/01/24)
Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.
CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF
-
Paragraph 0456, (2019/10/23)
Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by contacting them with CAPN1, CAPN2, and/or CAPN9 enzymes residing inside a subject. The compounds and composition can also be administered to a subject in order to treat a fibrotic disease or a secondary disease state or condition of a fibrotic disease.
Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides
-
, (2008/06/13)
Processes and intermediates for preparing compounds of Formula (I).
Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
-
, (2008/06/13)
PCT No. PCT/IB95/00442 Sec. 371 Date Dec. 2, 1997 Sec. 102(e) Date Dec. 2, 1997 PCT Filed Jun. 6, 1995 PCT Pub. No. WO96/39384 PCT Pub. Date Dec. 12, 1996Compounds of Formula (1) wherein R6 is carboxy, (C1-C8)alkoxycarbonyl, benzyloxycarbonyl, C(O)NR8R9 or C(O)R12 as glucogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.
